



Balfour Capital Group AbbVie Inc.

AbbVie Inc. is a global, research-driven biopharmaceutical company headquartered in North Chicago, Illinois. Established in 2013 following its spin-off from Abbott Laboratories, AbbVie focuses on developing innovative medicines in key therapeutic areas, including immunology, oncology, neuroscience, eye care, and aesthetics. The company's mission is to discover and deliver innovative medicines and solutions that address complex health issues and enhance people's lives.

1. Top 5 Competitors

AbbVie's primary competitors in the pharmaceutical industry include:

1. Johnson & Johnson (JNJ)
2. Pfizer Inc. (PFE)
3. Merck & Co., Inc. (MRK)
4. Bristol-Myers Squibb Company (BMY)

Eli Lilly and Company (LLY) These companies operate in similar therapeutic areas and compete with AbbVie in various markets.

2. Largest Institutional Shareholders

As of recent filings, the largest institutional shareholders of AbbVie are:

- The Vanguard Group, Inc. – 9.7% ownership
- BlackRock Inc. – 4.6% ownership
- State Street Corporation – 4.5% ownership

These institutions collectively hold a significant portion of AbbVie's outstanding shares.

3. Management Team

- Robert A. Michael – Chief Executive Officer
- Scott T. Reents – Executive Vice President, Chief Financial Officer
- Richard A. Gonzalez – Executive Chairman of the Board and Retired CEO

The leadership team brings extensive experience in the pharmaceutical industry, guiding AbbVie's strategic direction and operations.



Balfour Capital Group AbbVie Inc.

4. Revenue

AbbVie reported the following revenues:

- Q1 2025: \$13.343 billion, an 8.4% increase year-over-year
- Full Year 2024: \$56.33 billion, a 3.7% increase from 2023

The growth was driven by strong sales of immunology drugs Skyrizi and Rinvoq, which offset declines in Humira sales due to biosimilar competition.

5. Institutions with Buy Recommendations:

Several financial institutions have issued buy recommendations for AbbVie:

- Morgan Stanley: Maintained an "Overweight" rating with a price target of \$241
- MarketBeat: Reports a consensus recommendation of "Moderate Buy" from 26 brokerages

These endorsements reflect confidence in AbbVie's growth prospects and financial performance.

6. Analyst Sentiment Summary

Analyst sentiment toward AbbVie is generally positive:

- Consensus Rating: "Buy"
- Average Price Target: \$212.00, indicating a potential upside of approximately 12.8% from the current price

Analysts highlight the company's robust pipeline and successful transition from Humira to newer therapies like Skyrizi and Rinvoq.



Balfour Capital Group AbbVie Inc.

7. Insider Buying and Selling (Last 24 Months)

Over the past 24 months, AbbVie insiders have sold a total of 869,352 shares, amounting to approximately \$156.6 million.

Notably, there have been no reported insider purchases during this period, indicating a trend of net selling among insiders.

